China Oncology: an increasing burden and growth opportunity

With 50 % of global gastric, hepatic, and esophageal cancer cases and high lung cancer incidence, China Oncology market is a unique and challenging opportunity for multinational and local Biopharma.

BlueJet Consulting can help portfolio, launch and go-to-market strategy.

#commercialexcellence

#oncology

Continue reading